Journal Information
Vol. 32. Issue 2.
Pages 100-102 (February 1996)
Share
Share
Download PDF
More article options
Vol. 32. Issue 2.
Pages 100-102 (February 1996)
Full text access
Diseminación miliar con afectación pulmonar secundaria a inmunoterapia intravesical con bacilo de Calmette-Guérin
Visits
3552
C. Paredes Arranz*,1, J.F. de Frutos Arribas*, J. Calleja Escudero**, M. Blanco Cabero*, F. del Campo Matías*, M.C. Velasco***
* Sección de Neumología. Hospital del Río Hortega. Valladolid
** Servicio de Urología. Hospital del Río Hortega. Valladolid
*** Servicio de Anatomía Patológica. Hospital del Río Hortega. Valladolid
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics

Se describe el caso de un varón de 67 años sometido a resección transuretral e inmunoterapia con bacilo de Calmette-Guérin (BCG) por presentar un carcinoma transicional superficial de vejiga. Tras varias sesiones de instilación intravesical del preparado (BCG), el paciente desarrolló un cuadro de fiebre, astenia y anorexia persistente que motivó su ingreso hospitalario. Se realizaron diversas pruebas, estableciéndose el diagnóstico de diseminación miliar por BCG, que evolucionó fatalmente, a pesar del tratamiento tuberculostático.

La administración intravesical de BCG rara vez origina complicaciones graves por diseminación hematógena aunque, actualmente, parece ser más frecuente de lo que se pensaba.

La infección diseminada debe sospecharse en todo paciente que reciba BCG y con un cuadro clínico compatible. El conocimiento de esta complicación y la instauración precoz del tratamiento específico son la única medida que mejorará el pronóstico de esta importante complicación.

Palabras clave:
Inmunoterapia BCG
Diseminación miliar

We describe the case of a 67-years-old man who underwent transurethral resection and immunotherapy with Calmette-Guérin bacillus solution (CGB) for superficial transitional carcinoma of the bladder. After a series of intravesical irrigations with CGB, the patient developed fever, asthenia and persistent anorexia and was hospitalized. After testing he was diagnosed of miliary tuberculosis due to CGB and died in spite of tuberculostatic therapy.

Hematogenous dissemination, a rare but serious complication of vesical irrigation with CGB, is thought to be more common than previously suspected. It should be suspected in all patients receiving CGB when a compatible clinical pieture presents. An understanding of this complication and early establishment of specific treatment is the only wat to improve prognosis.

Key words:
Calmette-Guérin bacillus immunotherapy
Miliary tuberculosis
Full text is only aviable in PDF
Bibliografía
[1.]
A. Morales, D. Eidinger, A.W. Bruce.
Intracavitary bacillus Calmette-Guérin in te treatment of superficial bladder tumors.
J Urol, 116 (1973), pp. 180-183
[2.]
D.L. Lamm.
Bacillus Calmette-Guérin immunotherapy for bladder cancer.
J Urol, 134 (1985), pp. 40-47
[3.]
D.L. Lamm, P.M. Van der Meijden, A. Morales, S.A. Brosman, W.J. Catalona, H.W. Herr, et al.
Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer.
J Urol, 147 (1992), pp. 596-600
[4.]
D.L. Lamm, V.D. Stogdill, B.J. Stogdill, R.G. Crispen.
Complications of bacillus Calmette-Guérin immunotherapy in 1278 patients with bladder cancer.
J Urol, 135 (1985), pp. 272-274
[5.]
D.L. Lamm.
Systemic bacillus Calmette-Guérin infection after transuretral administration for superficial bladder carcinoma [Editorial.].
Urol, 142 (1989), pp. 1.074-1.075
[6.]
P.M. Van der Meidjen, F.M.J. Debruyne, P.A. Steerenberg, W.H. De Jong.
Aspects of nonspecific immunotherapy with BCG in superficial bladder cancer: an Over View.
Prog Clin Biol Res, 310 (1989), pp. 11-13
[7.]
S.A. Brosman.
The use of bacillus Calmette-Guérin in the therapy of bladder carcinoma in situ.
J Urol, 134 (1985), pp. 36-39
[8.]
H.Y. Marans, H.M. Bekirov.
Granulomatous hepatitis following intravesical bacillus Calmette-Guérin therapy for bladder carcinoma.
J Urol, 137 (1987), pp. 111-112
[9.]
A. Steg, D. Sicard, C. Leleu, B. Debre, L. Boccon-Gibod.
Systemic complications of intravesical BCG therapy for bladder cancer.
Lancet, 2 (1985), pp. 899
[10.]
D. Israel-Biet, A. Venet, A. Sandron, J.M. Ziza, J. Chretien.
Pulmonary complications of intravesical bacillus Calmette-Guérin immunotherapy.
Am Rev Respir Dis, 135 (1987), pp. 763-786
[11.]
P. Gregory, LeMense, M.D. Charlie Strange.
Granulomatous pneumonitis following intravesical BCG What therapy in needed?.
Chest, 106 (1994), pp. 1.624-1.626
[12.]
S. Resten, L. Title, B. Mullen, R. Grossman.
Pulmonary disease following BCG treatment.
Thorax, 45 (1990), pp. 709-710
[13.]
C. McParland, D.J. Cotton, K.S. Gowda, V.H. Hueppner, W. Thomson Martin, P.F. Weckworth.
Milliary Mycobacterium bovis induced by intravesical bacillus Calmette-Guérin immunotherapy.
Am Rev Respir Dis, 146 (1992), pp. 1.330-1.336
[14.]
M. Paleyew, D. Briedis, M. Libman, R.P. Michel, R.D. Levy.
Diseminated infection after intravesical BCG immunotherapy.
Chest, 104 (1993), pp. 307-309
[15.]
W.H. Rawls, D.L. Lamm, B.A. Lowe, E.D. Crawford, M.F. Sarosdy, J.E. Montie, H.B. Grossman, P.T. Scardino.
Fatal sepsis following intravesical bacillus Calmette-Guérin administration for bladder cancer.
J Urol, 144 (1990), pp. 1.328-1.330
[16.]
R.L. Deresiewicz, R.M. Stone, J.C. Aster.
Fatal disseminated mycobacterial infection following intravesical bacillus Calmette-Guérin.
J Urol, (1990), pp. 1331-1.334
[17.]
Canadian Center Statistics. Toronto. National Center Institute of Canada 1990; 322: 1.129-1.230.
Copyright © 1996. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?